Skip to content

SI-BONE, Inc. SIBN Free cash flow

Free cash flow at other companies

Stryker logo
StrykerSYK
$415M+227%
Alphatec Holdings logo
Alphatec HoldingsATEC
-$10.8M+27.9%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
IAR
Integra LifeSciencesIART
-$5.05M+87.4%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
Globus Medical logo
Globus MedicalGMED

Other financials

Income statement

See full
Revenue$52.6M+11.2%
Gross profit$41.9M+11.3%
Operating income-$5.1M+31.9%
Net income-$4.3M+33.8%
EPS (diluted)-$0.10+33.3%

Balance sheet

See full
Cash & equivalents$33.5M-18.6%
Total debt$42.9M+15.6%
Total equity$178.9M+7.0%
Total assets$242.7M+6.8%

Cash flow

See full
Operating cash flow-$2.4M+51.9%
CapEx$1.1M-48.0%

Valuation

See full
Market cap$743.29M+6.4%
Enterprise value$752.71M+8.4%
P/S3.6×-0.4×

Profitability

See full
Gross margin79.6%+0.3pp
Operating margin-9.7%-3.0pp
Net margin-8.1%-2.6pp
FCF margin-2.9%-1.2pp

Returns & leverage

See full
Return on equity-9.6%-2.7pp
Debt / equity0.2×0.0×
Current ratio10×+1.5×

Where this comes from

Calculated from SI-BONE, Inc.’s reported figures.

The official record: SI-BONE, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about SI-BONE, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SI-BONE, Inc.'s free cash flow?
SI-BONE, Inc. (SIBN) reported free cash flow of -$3.44M in Q1 2026.
How has SI-BONE, Inc.'s free cash flow changed year-over-year?
SI-BONE, Inc.'s free cash flow increased by 50.8% year-over-year, from -$6.98M to -$3.44M.
What is the long-term trend for SI-BONE, Inc.'s free cash flow?
Over 4 years (2021 to 2025), SI-BONE, Inc.'s free cash flow has grown at a -32.5% compound annual growth rate (CAGR), from -$45.92M to -$9.53M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.